Related Experiment Video

Updated: Aug 8, 2026

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease

Tomris Ozben1, Serkan Ozben2

  • 1Department of Biochemistry, Medical Faculty, Akdeniz University, Antalya, Turkey.

Clinical Biochemistry
|April 8, 2019
PubMed

Insights

Alzheimer's disease involves brain inflammation and amyloid beta plaques. Despite studies suggesting anti-inflammatory drugs could help, clinical trials have not yet proven successful for Alzheimer's disease treatment.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Key pathological hallmarks include amyloid beta (Aβ) deposition, neurofibrillary tangles, and neuronal loss.
  • Neuroinflammation, involving activated microglia, is implicated in AD pathogenesis.

Purpose of the Study:

  • To explore the role of inflammation in Alzheimer's disease.
  • To evaluate the potential of anti-inflammatory drugs in AD prevention or treatment.

Main Methods:

  • Review of epidemiological studies on anti-inflammatory drug use and AD incidence.
  • Analysis of clinical trial data for anti-inflammatory interventions in AD.

Main Results:

  • Epidemiological data suggested a potential link between anti-inflammatory drug use and reduced AD incidence.
  • Clinical trials investigating anti-inflammatory drugs for AD have not yielded successful outcomes.

Conclusions:

  • While inflammation is implicated in Alzheimer's disease, direct anti-inflammatory treatments have not proven effective in clinical trials.
  • Further research is needed to understand the complex role of neuroinflammation in AD and to develop targeted therapies.
Keywords:
Alzheimer's diseaseInflammationNSAIDsTreatment

More Related Videos

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...